RAD51 and non-small cell lung carcinoma: It is however tempting to speculate that Rad51 expression might also predict therapy response of the individual NSCLC patient on the basis of in vitro data, indicating the involvement of Rad51 activity in mechanisms of therapy resistance after the treatment of cells with DNA-damaging agents or irradiation (Henning and Stuerzbecher, 2003).